Skip To Main Content
Hannah Kitt on Muck Rack

Hannah Kitt

London
As seen in: medRxiv, BJGP (British Journal of General Practice), Medicine Matters Oncology, Medicine Matters Rheumatology, medwireNews
Covers:  Oncology and rheumatology

Get in touch with Hannah

Contact Hannah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Are we missing early HIV diagnoses in primary care?

|
By Hannah Kitt, Eilish Hart, Fiona Burns
| BJGP (British Journal of General Practice) Verified
Late HIV diagnosis increases the risk of death within a year of diagnosis 10-fold compared with when HIV is diagnosed promptly, causes significant morbidity, impacts quality of life, and can increase the risk of onward transmission.1 In 2024, 1 in 5 people (539/2746) newly diagnosed with HIV had advanced HIV2 (defined as being at significant risk of AIDS-defining illness with a CD4 count below 200 cells/mm3 … View Full Text
Open in Who Shared Issue with article?

Retrospective challenges to pre-exposure prophylaxis (PrEP) use among people living with HIV - A qualitative analysis using the COM-B framework.

|
By Hannah Kitt, Dolores Mullen, Carina Hoerst, Helen Corkin
| medRxiv
The authors have declared no competing interest. NA The author(s) received no specific funding for this work. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was reviewed and approved by the UKHSA Research Ethics and Governance Group (REGG), no. NR0260.
Open in Who Shared View Duplicates (17) Issue with article?

Lorlatinib benefits extend to NSCLC patients with brain metastases

|
By Hannah Kitt
| medwireNews Verified
medwireNews: Patients with advanced ALK-positive non-small-cell lung cancer (NSCLC) derive prolonged progression-free survival (PFS) from first-line treatment with lorlatinib regardless of the presence of brain metastases, post-hoc analyses indicate. The phase 3 CROWN trial showed that lorlatinib significantly improves PFS in patients with advanced ALK-positive NSCLC compared with crizotinib.
Open in Who Shared View Duplicates (2) Issue with article?
See all 498 articles